Compare JPMorgan Chase & Co (JPM) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Health Care Select Sector SPDR Fund — how do they compare? JPMorgan Chase & Co trades at $332.37 (market cap $880.98B), while Health Care Select Sector SPDR Fund trades at $169.99 (market cap $43.48B). The key difference: JPMorgan Chase & Co is far larger — about 20.3× Health Care Select Sector SPDR Fund's market cap, and JPMorgan Chase & Co pays a 1.99% dividend while Health Care Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Chase & Co for 127 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| JPM | XLV | |
|---|---|---|
Market Cap | $880.98B | $43.48B |
Volume | 7,721,661 | 11,121,431 |
Sector | Financials | — |
52-Week High | $365.18 | $175.68 |
52-Week Low | $282.84 | $141.95 |
Typical Hold Time | 127 Days | 100 Days |
Enterprise Value | $1.82T | — |
Dividend Yield | 1.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $329.58, down 0.51% with a bearish technical signal. The stock shows strong fundamentals with revenue growth from $181.85B in 2025 to $194.9B projected for 2026, and a net income margin of 33.38%. Recent earnings beat expectations in Q1 and Q2 2026, while analyst consensus remains positive with a $373.18 price target. However, negative cash flow trends and geopolitical risks noted by CEO Jamie Dimon present headwinds.
Outlook: JPM offers solid value with a P/E of 14.2 and high ROE of 18.43%, supported by earnings beats and institutional buying. Risks include sustained negative operating cash flow, rising debt-to-asset ratio (11.34% in 2024), and macroeconomic volatility. The stock is a hold for long-term investors, with upside to consensus target if earnings momentum continues.
XLV trades at $169.58 with a slight 0.46% daily gain amid bearish technical signals. The ETF faces selling pressure with moving averages indicating downward momentum while oscillators remain neutral. Recent news highlights XLV's competitive expense ratio of 0.08% and defensive healthcare sector positioning. Options activity shows increased put volume, suggesting some investor caution despite the fund's diversification across 61 healthcare stocks.
The healthcare ETF presents a cost-effective defensive play with potential upside if political volatility subsides post-elections. Key risks include sector-specific regulatory pressures and biotech trial failures impacting holdings. Current technical weakness near support at $166 requires monitoring for potential breakdown, though the fund's low fees and broad diversification provide stability during market uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
